Targeting Hirsutism: A New Approach

The document discussed a new approach to targeting hirsutism, emphasizing the importance of a thorough patient history to evaluate hair growth and distribution. It highlighted that 70%-80% of hirsutism cases are due to androgen-dependent disorders. Treatment options included mechanical hair removal methods, laser hair removal, and electrolysis. The document concluded that eflornithine HCl 13.9% cream (Vaniqa) was an effective FDA-approved topical treatment for reducing and potentially eradicating unwanted facial hair in women, with a favorable side effect profile, and should be considered by physicians for treating hirsutism.